BioPharma Resources

Drug Trial Radar · NCT06095089

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

355

Planned (sponsor's estimate)

Start

Nov 1, 2023

Primary completion

Jun 21, 2027

Study completion Jun 28, 2028

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Oct 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of the combination of JNJ-87189401 and JNJ-78278343 is, with or without apalutamide. Part 3 of this study evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with standard of care (SOC) lutetium Lu-177 vipivotide tetraxetan. Part 4 of this study further evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with JNJ-101556143 in participants with advanced prostate cancer.

Conditions

  • Prostatic Neoplasms

Interventions

  • JNJ-78278343Drug

    JNJ-78278343 will be administered.

  • JNJ-87189401Drug

    JNJ-87189401 will be administered.

  • ApalutamideDrug

    Apalutamide will be administered.

  • Lutetium Lu-177 Vipivotide TetraxetanDrug

    Lutetium Lu-177 Vipivotide Tetraxetan will be administered as SOC treatment.

  • JNJ-101556143Drug

    JNJ-101556143 will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1, 2C, 3 and 4: Number of Participants With Dose Limiting Toxicity (DLT)Time frame: Up to 21 days after first combination dose of study drugs
  2. Number of Participants with Adverse Events (AEs) by SeverityTime frame: Up to 4 years 8 months

Locations

22 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • Emory University Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • University Of Minnesota

    Minneapolis, Minnesota · Recruiting

  • START New Jersey

    East Brunswick, New Jersey · Recruiting

  • Herbert Irving Comprehensive Cancer Center Columbia University Medical Center

    New York, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Atrium Health Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Oregon Health And Science University

    Portland, Oregon · Recruiting

  • Sidney Kimmel Cancer Center - Jefferson Health

    Philadelphia, Pennsylvania · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • South Texas Accelerated Research Therapeutics, LLC (START)

    San Antonio, Texas · Recruiting

  • Swedish Medical Center

    Seattle, Washington · Recruiting

  • Greenslopes Private Hospital

    Greenslopes, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Australia · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, China · Recruiting

  • The First Affiliated Hospital of Xian Jiaotong University

    Xi'an, China · Recruiting

  • Institut Bergonie

    Bordeaux, France · Recruiting

  • Centre Leon Berard

    Lyon, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • The Cancer Institute Hospital of JFCR

    Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.